The effects of gastric bypass surgery on drug absorption and pharmacokinetics

Bibliography

• Haslam DW, James WP. Obesity. Lancet 2005;366(9492):1197-209
   PubMed Web of Science ®Google Scholar
• Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev 2007;29:1-5
   PubMed Web of Science ®Google Scholar
• Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol 2011;7(6):697-706
   PubMed Web of Science ®Google Scholar
• Shields M, Carroll MD, Ogden CL. Adult obesity prevalence in Canada and the United States. NCHS Data Brief 2011;56:1-8
   PubMedGoogle Scholar
• Anonymous. Obesity and overweight. Fact Sheet 311. In: Organization WH, editor. World health organization. edition. World Health Organization; Geneva: 2006
   Google Scholar
• Vincent HK, Heywood K, Connelly J, Hurley RW. Obesity and weight loss in the treatment and prevention of osteoarthritis. PM R 2012;4(5 Suppl):S59-67
   PubMedGoogle Scholar
• Whitlock G, Lewington S, Sherliker P, Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373(9669):1083-96
   PubMed Web of Science ®Google Scholar
• Must A, Spadano J, Coakley EH, The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523-9
   PubMed Web of Science ®Google Scholar
• Peeters A, Barendregt JJ, Willekens F, Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003;138(1):24-32
   PubMed Web of Science ®Google Scholar
• Jain R, Chung SM, Jain L, Implications of obesity for drug therapy: limitations and challenges. Clin Pharmacol Ther 2011;90(1):77-89
   PubMed Web of Science ®Google Scholar
• Maury E, Ehala-Aleksejev K, Guiot Y, Adipokines oversecreted by omental adipose tissue in human obesity. American journal of physiology Endocrinology and metabolism 2007;293(3):E656-65
   PubMed Web of Science ®Google Scholar
• Lago F, Gomez R, Conde J, Cardiometabolic comorbidities and rheumatic diseases: focus on the role of fat mass and adipokines. Arthritis Care Res 2011;63(8):1083-90
   Web of Science ®Google Scholar
• Gibbs H, Broom J, Brown J, The impact of obesity on drug prescribing in primary care. Br J Gen Pract 2005;55(519):743-9
   PubMed Web of Science ®Google Scholar
• Lau DC, Douketis JD, Morrison KM, Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2006;176(8):S1-13
   Web of Science ®Google Scholar
• Buchwald H, Avidor Y, Braunwald E, Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292(14):1724-37
   PubMed Web of Science ®Google Scholar
• Strychar I. Diet in the management of weight loss. CMAJ 2006;174(1):56-63
   PubMed Web of Science ®Google Scholar
• Shick SM, Wing RR, Klem ML, Persons successful at long-term weight loss and maintenance continue to consume a low-energy, low-fat diet. J Am Diet Assoc 1998;98(4):408-13
   PubMed Web of Science ®Google Scholar
• Tate DF, Jeffery RW, Sherwood NE, Wing RR. Long-term weight losses associated with prescription of higher physical activity goals. Are higher levels of physical activity protective against weight regain? Am J Clin Nutrit 2007;85(4):954-9
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335(7631):1194-9
   PubMed Web of Science ®Google Scholar
• Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006;116(1):33-5
   PubMed Web of Science ®Google Scholar
• Weisberg SP, McCann D, Desai M, Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112(12):1796-808
   PubMed Web of Science ®Google Scholar
• Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008;34(1):2-11
   PubMed Web of Science ®Google Scholar
• Kalitsky-Szirtes J, Shayeganpour A, Brocks DR, Piquette-Miller M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab Dispos 2004;32(1):20-7
   PubMed Web of Science ®Google Scholar
• Piquette-Miller M, Pak A, Kim H, Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res 1998;15(5):706-11
   PubMed Web of Science ®Google Scholar
• Vee ML, Lecureur V, Stieger B, Fardel O. Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab Dispos 2009;37(3):685-93
   PubMed Web of Science ®Google Scholar
• Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000;39(3):215-31
   PubMed Web of Science ®Google Scholar
• Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58(2):119-33
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010;49(2):71-87
   PubMed Web of Science ®Google Scholar
• Flechner SM, Kolbeinsson ME, Tam J, Lum B. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation 1989;47(5):806-10
   PubMed Web of Science ®Google Scholar
• Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995;39(6):684-7
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Abernethy DR, Locniskar A, Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61(1):27-35
   PubMed Web of Science ®Google Scholar
• Bowman SL, Hudson SA, Simpson G, A comparison of the pharmacokinetics of propranolol in obese and normal volunteers. Br J Clin Pharmacol 1986;21(5):529-32
   PubMed Web of Science ®Google Scholar
• Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010;82(4):314-23
   PubMed Web of Science ®Google Scholar
• Sanderink GJ, Le Liboux A, Jariwala N, The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther 2002;72(3):308-18
   PubMed Web of Science ®Google Scholar
• Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care 1995;18(7):986-91
   PubMed Web of Science ®Google Scholar
• Jang EH, Kim HK, Park CS, Kang JH. Increased expression of hepatic organic cation transporter 1 and hepatic distribution of metformin in high-fat diet-induced obese mice. Drug Metab Pharmacokinet 2010;25(4):392-7
   PubMed Web of Science ®Google Scholar
• Paxton JW, Briant RH. Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. Br J Clin Pharmacol 1984;18(5):806-10
   PubMed Web of Science ®Google Scholar
• Patel JP, Brocks DR. The effect of oral lipids and circulating lipoproteins on the metabolism of drugs. Expert Opin Drug Metab Toxicol 2009;5(11):1385-98
   PubMed Web of Science ®Google Scholar
• Varady KA, Lamarche B, Santosa S, Effect of weight loss resulting from a combined low-fat diet/exercise regimen on low-density lipoprotein particle size and distribution in obese women. Metabolism 2006;55(10):1302-7
   PubMed Web of Science ®Google Scholar
• Caraco Y, Zylber-Katz E, Berry EM, Levy M. Antipyrine disposition in obesity: evidence for negligible effect of obesity on hepatic oxidative metabolism. Eur J Clin Pharmacol 1995;47(6):525-30
   PubMed Web of Science ®Google Scholar
• Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci 1999;88(1):1-7
   PubMed Web of Science ®Google Scholar
• Emery MG, Fisher JM, Chien JY, CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003;38(2):428-35
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Clin Pharmacol Ther 1999;37(1):8-19
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983;101(6):873-80
   PubMed Web of Science ®Google Scholar
• Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther 1982;31(6):783-90
   PubMed Web of Science ®Google Scholar
• Naumnik B, Mysliwiec M. Renal consequences of obesity. Med Sci Monit 2010;16(8):RA163-70
   PubMed Web of Science ®Google Scholar
• Wurtz R, Itokazu G, Rodvold K. Antimicrobial dosing in obese patients. Clin Infect Dis 1997;25(1):112-18
   PubMed Web of Science ®Google Scholar
• Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84(6):1053-60
   PubMed Web of Science ®Google Scholar
• Henegar JR, Bigler SA, Henegar LK, Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001;12(6):1211-17
   PubMed Web of Science ®Google Scholar
• Anastasio P, Spitali L, Frangiosa A, Glomerular filtration rate in severely overweight normotensive humans. Am J Kidney Dis 2000;35(6):1144-8
   PubMed Web of Science ®Google Scholar
• Janmahasatian S, Duffull SB, Chagnac A, Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008;65(6):964-5
   PubMed Web of Science ®Google Scholar
• Cherrington NJ, Slitt AL, Li N, Klaassen CD. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab Dispos 2004;32(7):734-41
   PubMed Web of Science ®Google Scholar
• Varma MV, Rotter CJ, Chupka J, pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. Mol Pharm 2011;8(4):1303-13
   PubMedGoogle Scholar
• Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009;158(3):693-705
   PubMed Web of Science ®Google Scholar
• Hamad GG, Helsel JC, Perel JM, The effect of gastric bypass on the pharmacokinetics of serotonin reuptake inhibitors. Am J Psychiatry 2012;169:3:256-63
   PubMed Web of Science ®Google Scholar
• Padwal R, Klarenbach S, Wiebe N, Bariatric surgery: a systematic review of the clinical and economic evidence. J Gen Intern Med 2011;26(10):1183-94
   PubMed Web of Science ®Google Scholar
• Elder KA, Wolfe BM. Bariatric surgery: a review of procedures and outcomes. Gastroenterology 2007;132(6):2253-71
   PubMed Web of Science ®Google Scholar
• Buchwald H, Estok R, Fahrbach K, Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009;122(3):248-56; e245
   PubMed Web of Science ®Google Scholar
• Sugerman HJ, Wolfe LG, Sica DA, Clore JN. Diabetes and hypertension in severe obesity and effects of gastric bypass-induced weight loss. Ann Surg 2003;237(6):751-6; discussion 757-758
   PubMed Web of Science ®Google Scholar
• Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev 2010;11(1):41-50
   PubMed Web of Science ®Google Scholar
• Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide. 2008;Obes Surg 2009;19(12):1605-11
   Web of Science ®Google Scholar
• Chand B, Gugliotti D, Schauer P, Steckner K. Perioperative management of the bariatric surgery patient: focus on cardiac and anesthesia considerations. Cleve Clin J Med 2006;73(Suppl 1):S51-6
   PubMedGoogle Scholar
• Edwards A, Ensom MH. Pharmacokinetic effects of bariatric surgery. Ann Pharmacother 2012;46(1):130-6
   PubMed Web of Science ®Google Scholar
• Samuel I, Mason EE, Renquist KE, Bariatric surgery trends: an 18-year report from the International Bariatric Surgery Registry. Am J Surg 2006;192(5):657-62
   PubMed Web of Science ®Google Scholar
• Eldar S, Heneghan HM, Brethauer SA, Schauer PR. Bariatric surgery for treatment of obesity. Int J Obes (Lond) 2011;35(Suppl 3):S16-21
   PubMedGoogle Scholar
• Schernthaner G, Brix JM, Kopp HP, Schernthaner GH. Cure of type 2 diabetes by metabolic surgery? A critical analysis of the evidence in 2010. Diabetes Care 2011;34(Suppl 2):S355-60
   PubMedGoogle Scholar
• Christou N, Efthimiou E. Five-year outcomes of laparoscopic adjustable gastric banding and laparoscopic Roux-en-Y gastric bypass in a comprehensive bariatric surgery program in Canada. Can J Surg 2009;52(6):E249-58
   PubMed Web of Science ®Google Scholar
• Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 2006;63(19):1852-7
   PubMed Web of Science ®Google Scholar
• Bjorneklett A, Viddal KO, Midtvedt T, Nygaard K. Intestinal and gastric bypass. Changes in intestinal microecology after surgical treatment of morbid obesity in man. Scand J Gastroenterol 1981;16(5):681-7
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Bertch KE. Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet 1991;21(6):431-47
   PubMed Web of Science ®Google Scholar
• Darwich AS, Henderson K, Burgin A, Trends in oral drug bioavailability following bariatric surgery: Examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol 2012
   PubMed Web of Science ®Google Scholar
• Akkary E, Sidani S, Boonsiri J, The paradox of the pouch: prompt emptying predicts improved weight loss after laparoscopic Roux-Y gastric bypass. Surg Endosc 2009;23(4):790-4
   PubMed Web of Science ®Google Scholar
• Hogben CA, Schanker LS, Tocco DJ, Brodie BB. Absorption of drugs from the stomach. II. The human. J Pharmacol Exp Ther 1957;120(4):540-5
   PubMed Web of Science ®Google Scholar
• Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of common psychiatric medications in a Roux-en-Y gastric bypass model. Psychosomatics 2005;46(3):250-3
   PubMed Web of Science ®Google Scholar
• Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutrit Clin Pract 2003;18(2):131-5
   PubMedGoogle Scholar
• Smith A, Henriksen B, Cohen A. Pharmacokinetic considerations in Roux-en-Y gastric bypass patients. Am J Health Syst Pharm 2011;68(23):2241-7
   PubMed Web of Science ®Google Scholar
• Kim MS, Wang S, Shen Z, Differences in the pharmacokinetics of peroxisome proliferator-activated receptor agonists in genetically obese Zucker and sprague-dawley rats: implications of decreased glucuronidation in obese Zucker rats. Drug Metab Dispos 2004;32(9):909-14
   PubMed Web of Science ®Google Scholar
• Patel JP, Hamdy DA, El-Kadi AO, Brocks DR. Effect of Serum Lipoproteins on Stereoselective Halofantrine Metabolism by Rat Hepatocytes. Chirality 2012;24(7):558-65
   PubMed Web of Science ®Google Scholar
• Shayeganpour A, Korashy H, Patel JP, The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 2008;361(1-2):78-86
   PubMedGoogle Scholar
• Shedlofsky SI, Israel BC, McClain CJ, Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94(6):2209-14
   PubMed Web of Science ®Google Scholar
• Miller GD, Nicklas BJ, Fernandez A. Serial changes in inflammatory biomarkers after Roux-en-Y gastric bypass surgery. Surg Obes Relat Dis 2011;7(5):618-24
   PubMed Web of Science ®Google Scholar
• Considine RV, Sinha MK, Heiman ML, Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334(5):292-5
   PubMed Web of Science ®Google Scholar
• Izadpanah A, Barnard RJ, Almeda AJ, A Short-term Diet and Exercise Intervention Ameliorates Inflammation and Markers of Metabolic Health in Overweight/Obese Children. Am J Physiol Endocrinol Metab 2012;303(4):E542-50
   PubMed Web of Science ®Google Scholar
• Tandra S, Masters AR, Jones DR, Effect of Roux-en-Y Gastric Bypass Surgery on the Metabolism of the Orally Administered Medications. Digestive Disease Week; Chicago, IL; 2011
   Google Scholar
• Peters J, Oswald S, Haenisch S, Influence of Roux-en-Y gastric bypass surgery on the disposition of paracetamol, talinolol and amoxicillin in obese patients. American Society of Clinical Pharmacology and Therapeutics - Annual Meeting; Dallas, USA; 2011
   Google Scholar
• Wills SM, Zekman R, Bestul D, Tamoxifen malabsorption after Roux-en-Y gastric bypass surgery: case series and review of the literature. Pharmacotherapy 2010;30(2):217
   PubMed Web of Science ®Google Scholar
• Park DM, Shah DD, Egorin MJ, Beumer JH. Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. J Neurooncol 2009;93(2):279-83
   PubMed Web of Science ®Google Scholar
• Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med 2007;20(3):310-13
   PubMed Web of Science ®Google Scholar
• Pournaras DJ, Footitt D, Mahon D, Welbourn R. Reduced phenytoin levels in an epileptic patient following Roux-En-Y gastric bypass for obesity. Obes Surg 2011;21(5):684-5
   PubMed Web of Science ®Google Scholar
• Fuller AK, Tingle D, DeVane CL, Haloperidol pharmacokinetics following gastric bypass surgery. J Clin Psychopharmacol 1986;6(6):376-8
   PubMed Web of Science ®Google Scholar
• Skottheim IB, Stormark K, Christensen H, Significantly altered systemic exposure to atorvastatin acid following gastric bypass surgery in morbidly obese patients. Clin Pharmacol Ther 2009;86(3):311-18
   PubMed Web of Science ®Google Scholar
• Padwal RS, Ben-Eltriki M, Wang X, Effect of gastric bypass surgery on azithromycin oral bioavailability. J Antimicrob Chemother 2012;67(9):2203-6
   PubMed Web of Science ®Google Scholar
• Padwal RS, Gabr RQ, Sharma AM, Effect of gastric bypass surgery on the absorption and bioavailability of metformin. Diabetes Care 2011;34(6):1295-300
   PubMed Web of Science ®Google Scholar
• Rogers CC, Alloway RR, Alexander JW, Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant 2008;22(3):281-91
   PubMed Web of Science ®Google Scholar
• De Smet J, Colin P, De Paepe P, Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob Chemother 2012;67(1):226-9
   PubMed Web of Science ®Google Scholar
• Rubio IG, Galrao AL, Santo MA, Levothyroxine absorption in morbidly obese patients before and after Roux-En-Y gastric bypass (RYGB) surgery. Obes Surg 2012;22(2):253-8
   PubMed Web of Science ®Google Scholar
• Roerig JL, Steffen K, Zimmerman C, Preliminary comparison of sertraline levels in postbariatric surgery patients versus matched nonsurgical cohort. Surg Obes Relat Dis 2012;8(1):62-6
   PubMed Web of Science ®Google Scholar
• Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant 1996;10(5):414-19
   PubMed Web of Science ®Google Scholar
• Klockhoff H, Naslund I, Jones AW. Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery. Br J Clin Pharmacol 2002;54(6):587-91
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD. Appendix II. Design and optimization of dosage regimens: Pharmacokinetic data. In: Hardman JG, Limbard LE, Goodma-Gilman A, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th edition. McGraw-Hill; New York: 2001
   Google Scholar
• Maxon HR, Ritschel WA, Volle CP, Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine. Int J Clin Pharmacol Ther Toxicol 1983;21(8):379-82
   PubMedGoogle Scholar
• Trausch B, Oertel R, Richter K, Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 1995;16(5):403-14
   PubMed Web of Science ®Google Scholar
• Oswald S. (Poster) Influence of Roux-en-Y gastric bypass surgery on the disposition of paracetamol, talinolol and amoxicillin in obese patients. American Society of Clinical Pharmacology and Therapeutics - Annual Meeting; Dallas, USA; 2011
   Google Scholar
• Hunziker ME, Suehs BT, Bettinger TL, Crismon ML. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005;27(8):1126-43
   PubMed Web of Science ®Google Scholar
• Bareggi SR, Mundo E, Dell'Osso B, Altamura AC. The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol 2007;3(5):741-53
   PubMed Web of Science ®Google Scholar
• Klaassen CD, Aleksunes LM. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010;62(1):1-96
   PubMed Web of Science ®Google Scholar
• Graham GG, Punt J, Arora M, Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011;50(2):81-98
   PubMed Web of Science ®Google Scholar
• Kusuhara H, Ito S, Kumagai Y, Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011;89(6):837-44
   PubMed Web of Science ®Google Scholar
• Cho SK, Yoon JS, Lee MG, Chung JY 2011. Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants. Clin Pharmacol Ther 2011;89(3):416-21
   PubMed Web of Science ®Google Scholar
• Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999;39(10):995-1005
   PubMed Web of Science ®Google Scholar
• Maluenda F, Csendes A, De Aretxabala X, Alcohol absorption modification after a laparoscopic sleeve gastrectomy due to obesity. Obes Surg 2010;20(6):744-8
   PubMed Web of Science ®Google Scholar
• Pavlovsky C, Egorin MJ, Shah DD, Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. Pharmacotherapy 2009;29(9):1152-6
   PubMed Web of Science ®Google Scholar